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Methicillin-resistant Staphylococcus aureus (MRSA) has been a
common nosocomial pathogen since the 1960s, and has been
a major problem in hospitals worldwide. In 2006, the
European Antimicrobial Surveillance System (EARSS), a free
network that connects more than 600 laboratories in 28
European countries, recorded one incidence of MRSA per
100 000 patient-days, ranging from 0.2 in Denmark to 26.9
in Portugal (http://www.rivm.nl/earss/). In 2005, data from
The Surveillance Network-USA (TSN), an electronic surveil-
lance network that collects microbiology data from 300
clinical microbiology laboratories across the USA, reported
that MRSA rates were 59%, 55% and 48% for strains from
non-intensive-care unit (ICU) inpatients, ICU patients, and
outpatients, respectively [1]. Two meta-analyses showed that
bloodstream infections (BSIs) due to MRSA are associated
with almost two-fold higher mortality rates than those due
to methicillin-susceptible S. aureus [2,3]. Costs were signiﬁ-
cantly higher for MRSA BSIs than for methicillin-susceptible
S. aureus BSIs [4].
Risk factors include: degree of compliance with hand disin-
fection procedures, use of antimicrobials, underlying diseases,
prior hospitalization, surgery, duration of hospitalization,
central venous catheterization and endotracheal intubation,
enteral feeding, admission to the ICU, and nursing staff
workload [5–8]. A 1-year study, carried out at an ICU,
showed that urgent admission, values of APACHE II score at
24 h, bronchoscopy and days of staff deﬁcit were all indepen-
dent risk factors for acquisition of nosocomial MRSA. When
a simple stochastic model was ﬁtted, staff deﬁcit was the
only factor that was signiﬁcantly associated with cross-trans-
mission. It was predicted that a 12% improvement in adher-
ence to hand hygiene might have compensated for staff
shortage and prevented transmission during periods of over-
crowding, shared care, and high workload [6]. British and US
guidelines recommend that patients should be screened
routinely before ICU admission in a hospital where MRSA is
endemic [9,10].
A systematic review of isolation policies in the hospital
management of MRSA demonstrated that intensive con-
certed interventions, which include isolation policies, can
substantially reduce MRSA infections, even in settings with a
high level of endemic MRSA [11]. Recently, MRSA infections
have been diagnosed with increasing frequency upon hospital
admission. In a cohort study of 127 patients with MRSA bac-
teraemia, diagnosed upon hospital admission, independent
risk factors included a history of MRSA colonization or infec-
tion within 90 days, presence of a central venous catheter,
and skin ulcers or cellulitis [12,13]. A meta-analysis of MRSA
infections identiﬁed within 24–72 h of hospitalization docu-
mented a prevalence of community-acquired MRSA infec-
tions, deﬁned as infections in patients without any known
risk factors for MRSA, of £0.24% [14,15]. These ‘community-
acquired’ MRSA strains arise from two different patient pop-
ulations: those with true community-acquired infections due
to MRSA strains that have emerged de novo from commu-
nity-based S. aureus strains, and those with infections due to
healthcare-associated MRSA strains that have been acquired
in hospital or during a previous exposure to a healthcare
setting or intervention.
Increased adherence to hand-washing guidelines and
controlled use of antibiotics may be two of the few modiﬁ-
able factors offering a potential for primary prevention
of MRSA infection in the hospital setting. The efﬁcacy of a
multimodal, centrally coordinated, multisite hand hygiene
culture-change programme for reducing rates of MRSA was
assessed in Victorian hospitals. Increased compliance with
hand hygiene recommendations was associated with a signiﬁ-
cant reduction of MRSA BSIs [16,17].
The importance of a dose–effect association, supporting a
causal relationship between MRSA and antimicrobial drug
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use, has been demonstrated [13,18]. A meta-analysis including
24 230 patients showed a clear association between exposure
to antibiotics and MRSA colonization and infection. Subjects
who have been exposed to antibiotic therapy have an almost
two-fold greater chance of acquiring MRSA as opposed to
non-exposed subjects. This risk is almost three times greater
after the use of quinolones and glycopeptides [16].
For several years, conventional culture methods have been
considered the reference standard for detection of MRSA
colonization, but these can take at least 48–72 h to obtain a
result. In the absence of pre-emptive room isolation, this
delay might allow the spread of bacteria among hospitalized
patients. Recently, rapid methods for molecular detection of
MRSA-colonized patients have been developed. However,
studies on the impact of these new tests on the rate of
MRSA acquisition are extremely heterogeneous and showed
discordant results [17,18]. Therefore, for the moment, deﬁn-
itive recommendations cannot be made. As informed use
of hospital resources for detection of MRSA is important,
studies to analyse the cost-effectiveness of molecular tests in
different epidemiological situations are needed.
Therapy for MRSA infections has to be decided individu-
ally, taking into consideration the susceptibility patterns,
source of infection, presence of metastatic sites of infection,
comorbidities, and history of allergy. However, a number of
questions remain unsolved in the treatment of MRSA infec-
tions. Although glycopeptides are still the drugs of choice,
several concerns remain: reports of clinical failure with
vancomycin treatment, regardless of in vitro susceptibility;
increasing reports of MRSA strains with reduced vancomycin
susceptibility; difﬁculty in dosage monitoring of teicoplanin;
and lack of evidence of the efﬁcacy of combination therapy.
The increase in multidrug resistance, not only among
nosocomial but also among healthcare-associated and
community-acquired MRSA strains, is particularly worrisome.
Combination therapy may be considered in severe cases, as
for endocarditis unresponsive to standard monotherapy.
However, new trials are needed to deﬁne the role of
combination therapy in reducing mortality due to severe
MRSA infections. Among the newly developed antimicrobials,
linezolid may be the most versatile, as it can also be adminis-
tered orally. Daptomycin is the only drug among the newly
developed antimicrobials that has been approved for MRSA
BSI. Dalbavancin, telavancin and tigecycline look promising.
However, in order to update existing guidelines, new trials
are needed. At the moment, use of these drugs should be
carefully monitored, to assess their efﬁcacy and the risk of
development of resistance.
To address the impact and clinical relevance of new diag-
nostic and therapeutic approaches, the European Society of
Clinical Microbiology and Infectious Diseases sponsored a
consensus conference. The following reviews summarize the
consensus of opinion on that occasion.
National guidelines for the control and prevention of
MRSA do exist. These are increasingly evidence-based,
although not all guidelines involve a rigorous assessment of
the literature to determine the strength of the recommenda-
tions [19]. Few recommendations have acquired the highest
rating on the strength of evidence, and well-designed studies
of the many aspects of MRSA management and control are
lacking. Consensus among experts is thus important when
evidence is tenuous or well-performed studies are lacking.
Although it should be clearly stated that expert reports
and consensus based on clinical experience should be explic-
itly labelled as low-quality evidence, there remains a role for
expert opinion while better systems for rating the quality of
evidence and the strength of existing recommendations are
developed and adopted.
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